American Society of Clinical Oncology

SHERPA: White

People

  1. Hudis
    Hudis
  2. Norton
    Norton
  3. Dang
    Dang
  4. Modi
    Modi
  5. Seidman
    Seidman
  6. Chandarlapaty
    Chandarlapaty
  7. Iyengar
    Iyengar
  8. Lake
    Lake
  9. D'Andrea-Carlino
    D'Andrea-Carlino
  10. Goldfarb
    Goldfarb

Groups

  1. Breast Medicine Service (21)
  2. Department of Medicine (21)
  3. Solid Tumor Oncology Division (21)
  4. Survivorship Research (21)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (19)
  6. Epidemiology and Biostatistics (11)
  7. Biostatistics Service (10)
  8. Population Sciences Research Program (9)
  9. Radiology, Department of (9)
  10. Behavioral Sciences Service (8)
Search Within
  1. "Clifford Hudis"
  2. "Jose Baselga"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (8)
Groups
  1. Breast Medicine Service (21)
  2. Department of Medicine (21)
  3. Solid Tumor Oncology Division (21)
  4. Survivorship Research (21)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (19)
  6. Epidemiology and Biostatistics (11)

More Groups

People
  1. Clifford Hudis (21)
  2. Jose Baselga (21)
  3. Larry Norton (15)
  4. Sujata Patil (9)
  5. Andrew Seidman (8)
  6. Chau Dang (8)

More People

Years
  1. 2018 (1)
  2. 2017 (2)
  3. 2016 (2)
  4. 2015 (4)
  5. 2014 (4)
  6. 2013 (1)

More Years

Publications
  1. Journal of Clinical Oncology (21)

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Longer follow-up on clinical outcomes of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2 overexpressing metastatic breast cancer
    Meeting Abstract

    Wang, R.; Smyth, L. M.; Iyengar, N. M.; Modi, S.; Chandarlapaty, S.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer
    Meeting Abstract

    Wang, R.; Yu, A. F.; Steingart, R.; Patil, S.; Baselga, J.; Norton, L.; Hudis, C.; Dang, C. T.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Pilot trial of an implantable microdevice for in vivo drug sensitivity testing in patients with early stage, triple negative breast cancer receiving neoadjuvant therapy
    Meeting Abstract

    Traina, T. A.; Plitas, G.; Reis-Filho, J. S.; Morris, E. A.; Hughes, M.; Sung, J. S.; Patil, S.; Piscuoglio, S.; Park, S.; Greenberg, C.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Serial next generation sequencing (NGS) of cell free DNA (cfDNA) and clonal evolution of AKT1 E17K mutant tumors: Analyses from patients (pts) enrolled on a phase I basket study of an AKT inhibitor (AZD5363)
    Meeting Abstract

    Smyth, L. M.; Reichel, J. B.; Tang, J.; Patel, J. A. A.; Meng, F.; Selcuklu, S. D.; You, D.; Samoila, A.; Schiavon, G.; Li, B. T.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Meeting Abstract

    Smyth, L. M.; Iyengar, N. M.; Chandarlapaty, S.; Sugarman, S.; Comen, E. A.; Drullinsky, P.; Sklarin, N. T.; Traina, T. A.; Troso-Sandoval, T. A.; Patil, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center
    Meeting Abstract

    Fontes Santos De Teive Argolo, D.; Smyth, L. M.; Iyengar, N. M.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
    Journal Article

    Dang, C.; Iyengar, N.; Datko, F.; D'Andrea, G.; Theodoulou, M.; Dickler, M.; Goldfarb, S.; Lake, D.; Fasano, J.; Fornier, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of daily PI3K alpha inhibitor BYL719 plus letrozole (L) or exemestane (E) for patients (pts) with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Modi, S.; Datko, F. M.; Moynahan, M. E.; Zamora, S.; D'Andrea, G.; Lake, D.; Goldfarb, S. B.; Patil, S.; Singh, S.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save